Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2008

View Archived Issues

Extended-release hydrocodone/acetaminophen improves pain, function in osteoarthritis patients

SAR-113945 shows potential for osteoarthritic joint pain

Novel CB1 receptor antagonist profiled at Bristol-Myers Squibb

Telik enters into diabetes license agreement with ReceptorBio

Vertex initiates phase III REALIZE trial with telaprevir in HCV

Vion plans to conduct a phase III trial of Cloretazine in combination with AML and MDS therapy

Recent patent literature divulges novel treatment options for diabetes

New compounds for pulmonary hypertension reported in recent Concert patent

New treatments for autoimmune disorders disclosed in recent patents

4SC describes new compounds for urinary incontinence in recent patent

sc28AT potentiates tacrolimus effect on acute kidney allograft rejection in baboons

TY-027: a novel approach to treating neuropathic pain

Melior collaborates with AstraZeneca using theraTRACE discovery platform

Boehringer Ingelheim and Ablynx extend research collaboration in AD

Lilly completes acquisition of SGX

Noven enters license agreement with Procter & Gamble for HSDD patches

RegeneRx completes patient enrollment in phase II RGN-137 trial

Activx reports topline results from phase Ib and phase IIa clinical trials of KRP-1

EMEA accepts for review Arpida's MAA for intravenous iclaprim in cSSTI

Enobia begins testing of enzyme replacement therapy for hypophosphatasia

Dual P2X3/P2X2/3 purinergic receptor antagonists profiled at Roche

NovaRx initiates pivotal phase III trial for Lucanix in lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...